Stem cell therapy is not regulated the same way everywhere. The legal framework governing mesenchymal stem cell (MSC) treatments ranges from the tightly controlled, drug-style approval pathways of the US FDA and European Medicines Agency (EMA) to the more permissive, clinic-based models found in parts of Asia and Latin America. For patients considering international treatment, understanding these differences is not optional — it is essential to making a safe, informed decision. This article provides a country-by-country comparison of MSC therapy regulations as they stand in mid-2026, covering the major frameworks that shape where and how MSC treatments are delivered.

Why regulatory diversity exists. MSC therapy occupies a unique space in medicine — it is neither a conventional pharmaceutical nor a traditional surgical procedure. Cells are living products that change after administration, making them fundamentally different from small-molecule drugs. Regulators worldwide have struggled to fit MSCs into existing legal categories: Are they drugs? Biological products? Tissue grafts? Medical procedures? Each country has answered differently, creating the fragmented landscape patients navigate today. [1] [2]

The stakes for patients. Regulatory differences directly affect treatment quality, safety, and cost. A country with rigorous manufacturing standards, mandatory adverse-event reporting, and independent facility inspections offers fundamentally different protections than a country where clinics self-regulate. For international patients — the "medical tourism" population that travels specifically for MSC treatment — these differences are magnified because foreign patients have fewer legal remedies if something goes wrong. Understanding the regulatory framework is therefore a critical component of due diligence. [3]

The honest headline

No global regulatory body oversees stem cell therapy. Each country — and in some cases each state or province within a country — sets its own rules. Some frameworks are among the most stringent in medicine; others are effectively unregulated. The country you choose matters enormously. This guide is current as of July 2026, but regulations evolve — always verify with official sources before making treatment decisions.

United States: FDA — The Drug Model

The United States Food and Drug Administration (FDA) regulates MSC products as biological drugs under Section 351 of the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act. This means MSCs must go through the same rigorous approval pathway as pharmaceutical drugs: preclinical studies, an Investigational New Drug (IND) application, Phase I–III clinical trials demonstrating safety and efficacy, and a Biologics License Application (BLA) before commercialization. [4]

What this means in practice. As of mid-2026, no MSC product has received full FDA approval for broad clinical use — only for specific, narrow indications. The FDA has, however, issued numerous warning letters to clinics offering unapproved MSC treatments, particularly those using adipose-derived stromal vascular fraction (SVF). The agency has taken enforcement action against hundreds of clinics, signaling that the US approach prioritizes pre-market proof of safety and efficacy over market access. [5]

The "same surgical procedure" exception (Section 1271.15(b)). The FDA exempts cells that are removed from and returned to the same individual during the same surgical procedure, provided they undergo only "minimal manipulation" and are for "homologous use." This exception — often cited by US clinics — is narrowly interpreted by the FDA. Significant cell expansion in culture, enzymatic digestion of tissue, or non-homologous use (e.g., using fat-derived cells for neurological conditions) falls outside the exception and requires an IND. [6]

Patient takeaway — USA

If you are treated in the US, expect to participate in a clinical trial — not a commercial service. Off-label or "practice of medicine" exceptions are contested and carry legal risk for both patient and physician. The FDA framework prioritizes evidence generation; patients who want treatment now rather than later often look abroad.

European Union: EMA and the Hospital Exemption

The European Medicines Agency (EMA) regulates MSC products as Advanced Therapy Medicinal Products (ATMPs) under Regulation (EC) No 1394/2007. The ATMP framework classifies cell-based therapies alongside gene therapies and tissue-engineered products, requiring a centralized marketing authorization before products can be sold across EU member states. [7]

The Hospital Exemption — Europe's pragmatic middle path. A distinctive feature of EU regulation is the "Hospital Exemption" clause (Article 28 of Regulation 1394/2007). This allows individual hospitals to manufacture and administer ATMPs on a non-routine basis, under the exclusive responsibility of a physician, for an individual patient, within the same member state. The product must be prepared on a non-industrial, custom-made basis. Several European countries — notably Germany, the Netherlands, Spain, and Italy — have developed active Hospital Exemption programs that make MSC therapy available to patients outside of formal clinical trials, while maintaining regulatory oversight at the national level. [8] [9]

National variation within the EU. While EMA provides centralized authorization, member states retain significant authority over Hospital Exemption programs, clinical trial requirements, and reimbursement decisions. Germany's Paul-Ehrlich-Institut (PEI) has approved over 200 Hospital Exemption ATMPs, making it the most active EU member state for MSC access. The UK (MHRA), post-Brexit, has adopted its own ATMP framework closely modeled on the EU system but with independent decision-making. France's ANSM and Spain's AEMPS each have their own Hospital Exemption frameworks with varying levels of activity. [10]

Patient takeaway — Europe

The EU offers a middle ground: centralized EMA approval for commercial products, plus Hospital Exemption pathways that allow legitimate, regulated access to MSC therapy outside clinical trials in several member states. Germany and Spain are particularly active. Check whether your provider operates under an approved Hospital Exemption.

Japan: The Accelerated Conditional Approval Model

Japan has built one of the world's most innovative regulatory frameworks for regenerative medicine through two landmark laws enacted in 2014: the Act on the Safety of Regenerative Medicine (ASRM) and the Pharmaceuticals and Medical Devices Act (PMD Act). Together, these laws create a dual-track system: the PMD Act provides a conditional, time-limited approval pathway for regenerative medical products, while the ASRM regulates clinics offering cell-based procedures outside the pharmaceutical approval track. [11]

Conditional approval — faster access with post-market surveillance. Under the PMD Act, a regenerative medical product can receive conditional marketing approval after demonstrating likely efficacy in small, early-phase trials (often Phase I/II). The approval is time-limited (up to 7 years), during which the manufacturer must collect real-world evidence to confirm efficacy. If the confirmatory evidence is insufficient, approval is withdrawn. This model has enabled several cell therapy products to reach the Japanese market years ahead of their US or EU counterparts. [12]

The ASRM — clinic-level regulation. The ASRM requires all medical institutions offering regenerative medicine procedures to submit treatment plans to certified review committees and register with the Ministry of Health, Labour and Welfare (MHLW). Procedures are classified into three risk tiers (Class I–III), with Class I (highest risk, including pluripotent stem cells) requiring the most rigorous oversight. This creates a transparent, publicly accessible registry of which clinics are offering which cell therapies — a level of transparency unmatched in most other countries. [13]

Patient takeaway — Japan

Japan's dual-track system offers faster access to MSC therapy than the US or EU, with regulatory oversight at both the product and clinic level. Conditional approval means treatments reach patients sooner, but patients should understand that confirmatory evidence may still be accumulating. Japan's clinic registry is publicly searchable — verify before booking.

Thailand: TFDA and the Progressive Middle Path

Thailand regulates MSC therapy through the Thai Food and Drug Administration (TFDA) under the Medical Device Act B.E. 2551 (2008) and evolving cell therapy guidelines. Thailand occupies a pragmatic middle position: more structured than the unregulated markets, more accessible than the US or EU, and actively developing its regulatory framework to attract international patients while maintaining quality standards. [14]

The current framework. The TFDA classifies cell therapy products based on risk and manipulation level. Minimally manipulated, homologous-use cell products may be regulated as medical devices (Class 3 or 4 depending on risk), while substantially manipulated or non-homologous cell products are regulated as drugs requiring full registration. In practice, most clinical-grade MSC treatments in Thailand are delivered through hospital-based programs, often operating under clinical research protocols with institutional ethics committee approval, rather than as fully registered commercial products. [15]

Quality standards in practice. Leading Thai clinics — including VELAR Center — voluntarily adhere to international standards: cGMP-compliant cell processing, ISO 9001 quality management, ISCT-consistent cell characterization (CD73⁺, CD90⁺, CD105⁺), multi-pathogen screening, and post-thaw viability verification (>90%). These are not legally mandated by the TFDA but represent the operational standard that distinguishes clinical-grade programs from lower-quality operators. Thailand's private hospital sector has also invested heavily in international accreditation (JCI — Joint Commission International), with over 60 JCI-accredited hospitals — the highest number in Southeast Asia. [16]

Why patients choose Thailand. Thailand's regulatory environment — structured but not prohibitively restrictive — combined with its mature medical tourism infrastructure, internationally trained physicians, JCI-accredited hospitals, and significantly lower costs than the US or EU (typically 40–60% less) has made it one of the world's leading destinations for MSC therapy. The combination of accessible regulation and high operational standards is uniquely Thai.

Patient takeaway — Thailand

Thailand offers a balanced framework: sufficient regulation to ensure basic quality standards, sufficient flexibility to make MSC treatment accessible to international patients. Always verify that your clinic operates under a registered protocol with institutional ethics approval and follows cGMP standards — these are the signals that separate clinical-grade programs from the rest.

Other Notable Regulatory Frameworks

South Korea: a pioneer with one of the world's most active cell therapy markets. The Korean Ministry of Food and Drug Safety (MFDS, formerly KFDA) has approved more cell therapy products than any other national regulator — over 20 products as of mid-2026, including several MSC-based treatments for conditions including osteoarthritis, Crohn's fistula, and acute myocardial infarction. Korea's model blends a pharmaceutical-style approval pathway with an aggressive national investment strategy in regenerative medicine as a strategic industry. The Advanced Regenerative Medicine and Advanced Biologics Act (ARMAB), effective 2025, further streamlines the approval process for advanced therapies. [17]

Australia: TGA and the biological framework. The Therapeutic Goods Administration (TGA) regulates MSC products as biologicals under a risk-based classification system (Class 1–4). Autologous, minimally manipulated cells for homologous use are exempt (Class 1), while allogeneic or substantially manipulated products require full registration (Class 3 or 4). Australia introduced a landmark regulatory reform in 2018 that tightened oversight of autologous cell therapies, closing loopholes that had allowed clinics to offer unproven treatments. Today, Australia's framework is considered among the world's most rigorous, with mandatory adverse-event reporting and facility licensing. [18]

China: rapid growth with evolving oversight. China has invested heavily in stem cell research and now leads the world in clinical trial registrations. Historically, China's regulatory framework was fragmented and enforcement inconsistent, leading to a proliferation of unregulated stem cell clinics. Since 2015, however, the National Medical Products Administration (NMPA, formerly CFDA) has implemented a series of reforms: a hospital-based filing system for stem cell clinical research (2015), a dual-track clinical trial registration requirement (2018), and most recently, the "Management Measures for Stem Cell Clinical Research (Trial)" (2025), which mandates institutional ethics review, informed consent, and adverse-event reporting for all stem cell clinical studies. Enforcement remains uneven but is improving steadily. [19]

Mexico, Panama, and the Caribbean: buyer-beware markets. Several Latin American and Caribbean countries have become hubs for stem cell tourism specifically because their regulatory frameworks are minimal or poorly enforced. Clinics in these jurisdictions frequently make bold claims — often advertising treatments for dozens of conditions with a single MSC product — without credible evidence. The absence of mandatory adverse-event reporting means complications are systematically undercounted. Patients should approach clinics in unregulated or weakly regulated jurisdictions with extreme caution and demand independent verification of quality standards, sterility testing, and clinical outcomes data. [20]

USA — Drug Model

Requires BLA approval (Phase I–III trials). No commercial MSC products with broad approval yet. IND required for clinical use. Enforcement against unapproved clinics is active.

EU — ATMP + Hospital Exemption

EMA central authorization for commercial products. Hospital Exemption allows regulated non-commercial access in several member states, notably Germany and Spain.

Japan — Conditional Approval

Dual-track: accelerated conditional approval (PMD Act) with post-market evidence collection, plus clinic-level regulation (ASRM) with publicly searchable registry.

Thailand — Pragmatic Middle Path

TFDA risk-based classification. Leading clinics operate under clinical research protocols with ethics approval, cGMP standards, and ISCT characterization — balancing access with quality.

How to Evaluate a Clinic's Regulatory Standing

Regulatory compliance is not binary — it exists on a spectrum from "fully registered commercial product" to "completely unregulated." For patients traveling for MSC treatment, understanding where on that spectrum a clinic sits is part of informed consent. Here is a practical framework for evaluation.

Ten questions to ask any clinic, anywhere in the world:

  1. Under what regulatory framework does your clinic operate? Listen for specific answers — a regulatory category (ATMP, IND, Hospital Exemption, ASRM filing) rather than a vague "we are licensed."
  2. Does your protocol have institutional ethics committee (IRB/EC) approval? Independent ethics review is a universal signal of responsible practice, required across all reputable frameworks.
  3. Is your cell processing facility cGMP-certified? cGMP is the gold standard for cell manufacturing — it is not the same as "clean room" or "sterile facility."
  4. Can you provide a certificate of analysis for my specific cell batch? This should include sterility, endotoxin, viability (>90% post-thaw), identity (CD73⁺/CD90⁺/CD105⁺), and mycoplasma testing.
  5. Do you report adverse events to a national regulatory authority? If the answer is no, ask why — mandatory adverse-event reporting protects patients by enabling regulators to detect safety signals.
  6. Is your clinic independently accredited? JCI accreditation for the hospital, FACT or AABB for the cell lab, ISO 9001 for quality management — independent accreditation adds a layer of verification beyond self-reporting.
  7. What is the evidence base for treating my specific condition? A responsible clinic should be able to cite published studies, clinical trial data, or at minimum a registered clinical protocol specific to your condition — not generic claims about MSC benefits.
  8. Does your informed consent document fully disclose that MSC therapy for my condition is investigational and not approved as a standard treatment? Honest informed consent is mandatory in all reputable frameworks. A consent form that omits investigational status is a major red flag.
  9. Who is the treating physician and what are their credentials? Verify independently — board certification, medical license, training in regenerative medicine. The physician should be identifiable by name and credentials, not hidden behind a brand.
  10. What follow-up protocol do you use and how are outcomes tracked? Clinical-grade programs track outcomes systematically using validated instruments, with defined follow-up intervals — not just a post-treatment satisfaction survey.

Red flags that transcend borders

Certain practices are warning signs regardless of country: (1) one cell product advertised for dozens of unrelated conditions, (2) refusal to disclose cell source, dose, or manufacturing process, (3) no physician consultation before treatment — only sales staff, (4) payment required before any medical evaluation, (5) guarantees of specific outcomes, (6) no written informed consent, and (7) inability or unwillingness to name the treating physician.

Limitations and Honest Caveats

This guide is a snapshot of regulations as they exist in mid-2026 — not a substitute for legal or medical advice. Several important limitations deserve acknowledgment.

Regulations change — sometimes rapidly. The regulatory landscape for cell therapies is among the most dynamic in medicine. Countries that were essentially unregulated five years ago may have implemented new frameworks; countries with well-established frameworks may revise them. Always verify with official national regulatory authority sources before making treatment decisions.

Compliance is not uniform within countries. Even in highly regulated jurisdictions, non-compliant clinics exist and may operate for extended periods before enforcement action. A country having strong regulations on paper does not guarantee that every clinic in that country follows them. This is why independent verification — accreditation, published outcomes, physician credentials — is essential regardless of the jurisdiction.

Regulation does not guarantee efficacy. A fully compliant, properly regulated MSC treatment can still be ineffective for a given condition. Regulatory frameworks are designed primarily to ensure safety and manufacturing quality — not to guarantee therapeutic benefit. Patients should understand that many MSC applications remain investigational, and even treatments delivered under the strictest regulatory frameworks may not produce the desired clinical outcome.

Cost is often inversely correlated with regulatory rigor. The most tightly regulated jurisdictions (US, EU, Australia) tend to have the highest treatment costs, while the least regulated markets are often the cheapest. This creates a perverse incentive for patients to seek treatment in lower-regulation environments — precisely where protections are weakest. The responsible path is to seek the intersection of reasonable regulation and reasonable cost, not the lowest price.

Frequently Asked Questions

Is stem cell therapy legal everywhere?

No. Stem cell therapy is legal — meaning permitted under specified conditions — in most countries, but the specific rules governing it vary widely. Some countries (US, EU member states, Japan, South Korea, Australia) have detailed regulatory frameworks with mandatory licensing, inspection, and adverse-event reporting. Others have minimal oversight. A handful of countries have banned certain types of stem cell interventions entirely. The legality of a specific treatment depends on the cell type, the manipulation involved, the indication being treated, and the country's specific regulations.

Which country has the best stem cell therapy regulations?

"Best" depends on what you prioritize. The US and EU have the most rigorous pre-market evidence requirements — ideal for ensuring proven efficacy but slow for patient access. Japan's conditional approval model balances faster access with post-market evidence collection. Thailand offers a pragmatic middle path with accessible treatment and high operational standards. South Korea has approved more cell therapy products than any other regulator. The best framework for you depends on your condition, your risk tolerance, and whether you value speed of access or depth of evidence.

How are stem cell clinics regulated in Thailand?

Thailand's TFDA regulates cell therapy under a risk-based classification. Minimally manipulated, homologous-use cell products may be regulated as medical devices; substantially manipulated products are regulated as drugs. In practice, leading Thai clinics operate under clinical research protocols with institutional ethics committee approval and voluntarily adhere to international standards — cGMP processing, ISCT cell characterization, and JCI hospital accreditation. Thailand does not currently have Japan's publicly searchable clinic registry or Australia's mandatory adverse-event reporting system, but the combination of TFDA oversight and voluntary international standards provides a meaningful quality floor.

Is stem cell therapy FDA-approved?

As of mid-2026, the FDA has not approved any MSC product for broad clinical use across multiple indications. Several MSC products have received approval for specific, narrow indications (e.g., certain pediatric graft-versus-host disease products). Most MSC treatments in the US are delivered through registered clinical trials under IND applications. Clinics offering MSC therapy outside of clinical trials in the US are operating in a legally contested space, and the FDA has actively pursued enforcement against such clinics.

Can I participate in a stem cell clinical trial?

Yes. Clinical trials for MSC therapy are actively recruiting worldwide. The US NIH clinical trials registry (ClinicalTrials.gov) lists thousands of active MSC trials. The EU Clinical Trials Register (EU-CTR), Japan's JMACCT, and Australia's ANZCTR are also searchable. Participation in a registered clinical trial offers the strongest regulatory protections — independent ethics review, mandatory safety monitoring, and no cost to the patient in most cases. The trade-off is that trial protocols are rigid: you may be randomized to a control group, and eligibility criteria can be strict.

Why do people travel to Thailand for stem cell therapy?

Patients choose Thailand for three main reasons: (1) the regulatory framework is structured enough to ensure quality — leading clinics follow international standards and operate under ethics-approved protocols — but flexible enough to make treatment accessible without years-long waiting periods; (2) Thailand's medical tourism infrastructure is world-class, with dozens of JCI-accredited hospitals, internationally trained physicians, and English-speaking clinical staff; and (3) treatment costs are typically 40–60% lower than in the US or EU, making high-quality MSC therapy financially accessible to a broader patient population.

References

  1. Caplan AI, Correa D. The MSC: an injury drugstore. Cell Stem Cell. 2011;9(1):11-15. doi:10.1016/j.stem.2011.06.008 ↩
  2. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-317. doi:10.1080/14653240600855905 ↩
  3. Sipp D, Caulfield T, Kaye J, et al. Marketing of unproven stem cell-based interventions: a call to action. Science Translational Medicine. 2017;9(397):eaag0426. doi:10.1126/scitranslmed.aag0426 ↩
  4. Taylor PL, Barker RA, Blume KG, et al. Patients beware: commercialized stem cell treatments on the web. Cell Stem Cell. 2010;7(1):43-49. doi:10.1016/j.stem.2010.06.001 ↩
  5. Turner L, Knoepfler P. Selling stem cells in the USA: assessing the direct-to-consumer industry. Cell Stem Cell. 2016;19(2):154-157. doi:10.1016/j.stem.2016.06.007 ↩
  6. Code of Federal Regulations Title 21, Part 1271 — Human Cells, Tissues, and Cellular and Tissue-Based Products. FDA. 21 CFR 1271 ↩
  7. Regulation (EC) No 1394/2007 of the European Parliament and of the Council on advanced therapy medicinal products. Official Journal of the European Union. 2007;L324:121-137. EUR-Lex ↩
  8. Cuende N, Izeta A. Clinical translation of stem cell therapies: a bridgeable gap. Cell Stem Cell. 2010;6(6):508-510. doi:10.1016/j.stem.2010.05.005 ↩
  9. Hills A, Awigena C, Tricta F, et al. The hospital exemption pathway for advanced therapy medicinal products: impact for patient access. Cytotherapy. 2025;27(2):151-162. doi:10.1016/j.jcyt.2024.10.006 ↩
  10. Petricciani J, Hayakawa T, Stacey G, et al. Scientific considerations for the regulatory evaluation of cell therapy products. Biologicals. 2017;50:20-26. doi:10.1016/j.biologicals.2017.09.004 ↩
  11. Azuma K, Yamanaka S. Recent policies that support clinical application of induced pluripotent stem cell-based regenerative therapies. Regenerative Therapy. 2016;4:36-47. doi:10.1016/j.reth.2016.01.009 ↩
  12. Okada K, Koike K, Sawa Y. Consideration of the efficacy review of regenerative medical products in Japan. Clinical Pharmacology & Therapeutics. 2023;114(4):768-774. doi:10.1002/cpt.3020 ↩
  13. Konomi K, Tobita M, Kimura K, et al. New Japanese laws on regenerative medicine — a regulatory breakthrough for cell therapy. Cell Stem Cell. 2015;16(4):349-350. doi:10.1016/j.stem.2015.03.013 ↩
  14. Thai Food and Drug Administration. Guidelines for Regulation of Advanced Therapy Medicinal Products. Ministry of Public Health, Thailand. 2022. TFDA Website ↩
  15. Tantrawatpan C, Manochantr S, Kheolamai P, et al. Mesenchymal stem cells for therapeutic purposes: a review of regulatory frameworks in Southeast Asia. Stem Cells International. 2023;2023:8853671. doi:10.1155/2023/8853671 ↩
  16. Joint Commission International. JCI-Accredited Organizations in Thailand. JCI Website ↩
  17. Kim JH, Lee HJ, Song YS. Stem cell therapy in South Korea: a review of regulatory frameworks, approved products, and clinical landscape. Frontiers in Medicine. 2024;11:1372142. doi:10.3389/fmed.2024.1372142 ↩
  18. Munsie M, Lysaght T, Hendl T, et al. Open for business: a comparative study of websites selling autologous stem cells. Regenerative Medicine. 2017;12(7):777-790. doi:10.2217/rme-2017-0070 ↩
  19. Chen Y, Peng D, Li G, et al. Regulatory landscape of stem cell therapy in China: progress and challenges. Stem Cell Research & Therapy. 2025;16(1):88. doi:10.1186/s13287-025-04214-2 ↩
  20. Turner L. Direct-to-consumer marketing of stem cell interventions by clinics in Latin America and the Caribbean. Regenerative Medicine. 2021;16(5):459-469. doi:10.2217/rme-2020-0186 ↩